Literature DB >> 10556171

Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease.

F E Hargreave1, R Leigh.   

Abstract

The application of sputum induction and refined methods of sputum examination has provided the opportunity to examine cell and molecular markers of airway inflammation in asthma, COPD, and other airway diseases. The measurements are relatively noninvasive and can be applied safely, with care, even in more severe exacerbations of asthma and severe COPD. Induced sputum examination can be applied at random and repeatedly and gives results that are reproducible, valid, and responsive to changes in treatment. An eosinophilic bronchitis, defined as sputum eosinophilia, is typical of asthma but can also occur in patients with a chronic cough without asthma, and in some patients with COPD in whom the classic inflammatory response is neutrophilic without eosinophilia. When eosinophilia occurs in COPD, it has been considered to be the result of cigarette smoking but it may be due to other causes. The clinical importance of eosinophilic bronchitis is that it responds to treatment with corticosteroid. In contrast, there is increasing evidence that an absence of sputum eosinophilia is associated with steroid resistance. Hargreave FE, Leigh R. Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease.

Entities:  

Mesh:

Year:  1999        PMID: 10556171     DOI: 10.1164/ajrccm.160.supplement_1.14

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  16 in total

1.  Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy study.

Authors:  K Amin; A Ekberg-Jansson; C-G Löfdahl; P Venge
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

2.  Sputum proteomics in inflammatory and suppurative respiratory diseases.

Authors:  Robert D Gray; Gordon MacGregor; Donald Noble; Margaret Imrie; Maria Dewar; A Christopher Boyd; J Alastair Innes; David J Porteous; Andrew P Greening
Journal:  Am J Respir Crit Care Med       Date:  2008-06-19       Impact factor: 21.405

3.  Cough, airway inflammation, and mild asthma exacerbation.

Authors:  A B Chang; V A Harrhy; J Simpson; I B Masters; P G Gibson
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

Review 4.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  Identification and validation of nebulized aerosol devices for sputum induction.

Authors:  Warren J Davidson; John Dennis; Stephanie The; Belinda Litoski; Cora Pieron; Richard Leigh
Journal:  Can Respir J       Date:  2013-11-28       Impact factor: 2.409

6.  Sputum neutrophilia can mask eosinophilic bronchitis during exacerbations.

Authors:  Liesel D'silva; Christopher J Allen; Frederick E Hargreave; Krishnan Parameswaran
Journal:  Can Respir J       Date:  2007 Jul-Aug       Impact factor: 2.409

7.  Cough: are children really different to adults?

Authors:  Anne B Chang
Journal:  Cough       Date:  2005-09-20

8.  Patterns of inflammation and the use of reversibility testing in smokers with airway complaints.

Authors:  Niels H Chavannes; Juanita H J Vernooy; Tjard R J Schermer; Jan A Jacobs; Mieke A Dentener; Chris van Weel; Onno C P van Schayck; Emiel F M Wouters
Journal:  BMC Pulm Med       Date:  2006-06-01       Impact factor: 3.317

Review 9.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01

10.  Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD.

Authors:  M Bafadhel; S Saha; R Siva; M McCormick; W Monteiro; P Rugman; P Dodson; I D Pavord; P Newbold; C E Brightling
Journal:  Respiration       Date:  2009-05-27       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.